Key result
Aortic stented porcine xenografts linked to ~96% 10-year freedom from SVD versus double valve replacement.
Why the study?
The study aimed to evaluate long-term results after stented porcine xenograft implantation with Linx anticalcification treatment in elderly patients undergoing aortic and/or mitral valve replacement.
Does the Epic stented porcine xenograft provide acceptable long-term survival and freedom from valve-related complications in elderly patients requiring valve replacement?
Cohort (n=2,544)
Does the Epic stented porcine xenograft provide acceptable long-term survival and freedom from valve-related complications in elderly patients requiring valve replacement?
The Epic stented porcine xenograft demonstrates acceptable long-term survival and low rates of structural valve deterioration at 10 years in an elderly, all-comers population requiring valve replacement.
Answers are grounded in this paper and cite their sources.
Supports Epic xenograft use in elderly patients; leaves open randomized comparisons to other bioprostheses.
OBJECTIVES: The aim of this study was to evaluate the results after stented porcine xenograft implantation with Linx™ anticalcification treatment in the aortic and/or mitral position in elderly patients. METHODS: Over a decade, a total of 2544 patients receiving aortic (AVR = 1920), mitral (MVR = 347) or double valve (DVR = 277) replacement (between November 2001 and March 2012) were evaluated. The study was designed on an 'all comers' basis including all patients with elective, urgent or emergent need for valve replacement. Outcome was assessed by reviewing the prospectively acquired hospital database as well as regular follow-up information obtained by annual written interviews. RESULTS: Mean patient age was 76.5 ± 6 (AVR), 73.8 ± 7 (MVR) and 74.2 ± 7 (DVR) years, respectively; 54.2%/41.9%/42.0% were male, and active endocarditis was diagnosed in 4.5%/19.9%/22.1%; indication for valve surgery and the logistic EUROSCORE I predicted risk for mortality was 15.4 ± 15%/19.9 ± 19%/22.3 ± 21%, respectively. Concomitant mitral valve repair was required in 196 (10.2%) (AVR) patients; coronary artery bypass graft surgery (CABG) in 840 (43.8%) (AVR), 82 (23.7%) (MVR) and 94 (34.1%) (DVR) patients; cryoablation in 232 (12.1%)/81 (23.4%)/67 (24.3%) patients and surgery on the thoracic aorta in 166 (8.7%)/12 (3.5%)/41 (14.9%) patients, respectively. The mean follow-up was 4.5 ± 3.5 years. The rate of freedom from endocarditis after 10 years was 98.3 ± 0.4%/97.5 ± 1.0%/97.4 ± 1.6% (P = n.s.). The rate of freedom from structural valve disease was 96.3 ± 0.6%/93.8 ± 2.4%/92.8 ± 2.2% (AVR versus DVR, P = 0.009), and from thromboembolic events was 94.8 ± 1.0%/91.5 ± 2.9%/97.9 ± 1.3%. The 30-day survival rate was 97.3 ± 0.4%/95.1 ± .1.2%/92.8 ± 1.6% and the 10-year survival rate was 42.1 ± 1.5%/33.9 ± 4.7%/22.1 ± 7.1%, respectively. CONCLUSIONS: The Epic™ stented porcine xenograft is associated with acceptable survival, with large proportions of patients free from valve-related complications and freedom from valve reintervention for all older, in-coming patients.
No takes yet. Share an insight, caveat, or question.
Lehmann et al. (2015) conducted a cohort in Aortic, mitral, or double valve replacement (n=2,544). Stented porcine xenograft (Epic) implantation was evaluated on Freedom from structural valve disease at 10 years (AVR vs DVR) (p=0.009). Stented porcine xenograft implantation in elderly patients resulted in 10-year freedom from structural valve disease of 96.3% for aortic versus 92.8% for double valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: